JP2002535015A5 - - Google Patents
Download PDFInfo
- Publication number
- JP2002535015A5 JP2002535015A5 JP2000596368A JP2000596368A JP2002535015A5 JP 2002535015 A5 JP2002535015 A5 JP 2002535015A5 JP 2000596368 A JP2000596368 A JP 2000596368A JP 2000596368 A JP2000596368 A JP 2000596368A JP 2002535015 A5 JP2002535015 A5 JP 2002535015A5
- Authority
- JP
- Japan
- Prior art keywords
- detecting
- gene
- heteroduplex
- administering
- target
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Pending
Links
- 238000000034 method Methods 0.000 description 19
- 230000000692 anti-sense effect Effects 0.000 description 13
- 108091032973 (ribonucleotides)n+m Proteins 0.000 description 9
- 108090000623 proteins and genes Proteins 0.000 description 9
- 108091027305 Heteroduplex Proteins 0.000 description 7
- 150000001875 compounds Chemical class 0.000 description 6
- 125000004573 morpholin-4-yl group Chemical group N1(CCOCC1)* 0.000 description 6
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 description 4
- 239000003814 drug Substances 0.000 description 4
- 230000014509 gene expression Effects 0.000 description 4
- 230000008685 targeting Effects 0.000 description 4
- 229940124597 therapeutic agent Drugs 0.000 description 4
- 108091081024 Start codon Proteins 0.000 description 3
- 230000000295 complement effect Effects 0.000 description 3
- 108020004999 messenger RNA Proteins 0.000 description 3
- 239000002773 nucleotide Substances 0.000 description 3
- 125000003729 nucleotide group Chemical group 0.000 description 3
- 229910052698 phosphorus Inorganic materials 0.000 description 3
- 239000011574 phosphorus Substances 0.000 description 3
- 101001030211 Homo sapiens Myc proto-oncogene protein Proteins 0.000 description 2
- 101710163270 Nuclease Proteins 0.000 description 2
- OAICVXFJPJFONN-UHFFFAOYSA-N Phosphorus Chemical compound [P] OAICVXFJPJFONN-UHFFFAOYSA-N 0.000 description 2
- 241000700605 Viruses Species 0.000 description 2
- 210000001124 body fluid Anatomy 0.000 description 2
- 201000010099 disease Diseases 0.000 description 2
- 238000009396 hybridization Methods 0.000 description 2
- 208000015181 infectious disease Diseases 0.000 description 2
- 230000003834 intracellular effect Effects 0.000 description 2
- 230000002062 proliferating effect Effects 0.000 description 2
- FWMNVWWHGCHHJJ-SKKKGAJSSA-N 4-amino-1-[(2r)-6-amino-2-[[(2r)-2-[[(2r)-2-[[(2r)-2-amino-3-phenylpropanoyl]amino]-3-phenylpropanoyl]amino]-4-methylpentanoyl]amino]hexanoyl]piperidine-4-carboxylic acid Chemical compound C([C@H](C(=O)N[C@H](CC(C)C)C(=O)N[C@H](CCCCN)C(=O)N1CCC(N)(CC1)C(O)=O)NC(=O)[C@H](N)CC=1C=CC=CC=1)C1=CC=CC=C1 FWMNVWWHGCHHJJ-SKKKGAJSSA-N 0.000 description 1
- 206010028980 Neoplasm Diseases 0.000 description 1
- 239000010839 body fluid Substances 0.000 description 1
- 201000011510 cancer Diseases 0.000 description 1
- 230000008878 coupling Effects 0.000 description 1
- 238000010168 coupling process Methods 0.000 description 1
- 238000005859 coupling reaction Methods 0.000 description 1
- 238000001727 in vivo Methods 0.000 description 1
- 238000012544 monitoring process Methods 0.000 description 1
- 230000035772 mutation Effects 0.000 description 1
- 230000001105 regulatory effect Effects 0.000 description 1
- 230000001225 therapeutic effect Effects 0.000 description 1
- 210000002700 urine Anatomy 0.000 description 1
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US11784699P | 1999-01-29 | 1999-01-29 | |
| US60/117,846 | 1999-01-29 | ||
| PCT/US2000/002475 WO2000045167A2 (en) | 1999-01-29 | 2000-01-28 | Non-invasive method for detecting target rna |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| JP2002535015A JP2002535015A (ja) | 2002-10-22 |
| JP2002535015A5 true JP2002535015A5 (enExample) | 2007-02-08 |
Family
ID=22375152
Family Applications (2)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2000596368A Pending JP2002535015A (ja) | 1999-01-29 | 2000-01-28 | 標的ｒｎａを検出するための非侵襲性方法 |
| JP2000596139A Pending JP2002537230A (ja) | 1999-01-29 | 2000-01-29 | ｃ−ｍｙｃのアンチセンス標的化による再狭窄の処置方法 |
Family Applications After (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2000596139A Pending JP2002537230A (ja) | 1999-01-29 | 2000-01-29 | ｃ−ｍｙｃのアンチセンス標的化による再狭窄の処置方法 |
Country Status (9)
| Country | Link |
|---|---|
| US (1) | US6365351B1 (enExample) |
| EP (2) | EP1173561A2 (enExample) |
| JP (2) | JP2002535015A (enExample) |
| KR (2) | KR20010102992A (enExample) |
| AT (1) | ATE445700T1 (enExample) |
| AU (2) | AU778057B2 (enExample) |
| CA (2) | CA2360997A1 (enExample) |
| DE (1) | DE60043149D1 (enExample) |
| WO (2) | WO2000045167A2 (enExample) |
Families Citing this family (49)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US20010024783A1 (en) * | 1999-01-29 | 2001-09-27 | Avi Biopharma, Inc. | Non-invasive method for detecting target RNA |
| AU5752601A (en) * | 2000-05-04 | 2001-11-12 | Avi Biopharma Inc | Splice-region antisense composition and method |
| AU6319701A (en) * | 2000-05-17 | 2001-11-26 | Avi Biopharma Inc | Antisense enzyme inhibitors for metabolic redirection |
| WO2002018656A2 (en) * | 2000-08-30 | 2002-03-07 | Avi Biopharma, Inc. | Method for analysis of oligonucleotide analogs |
| US7754238B2 (en) | 2002-05-03 | 2010-07-13 | Avi Biopharma, Inc. | Delivery of microparticle-conjugated drugs for inhibition of stenosis |
| AU2004235396B2 (en) * | 2003-04-29 | 2010-11-25 | Sarepta Therapeutics, Inc. | Compositions for enhancing transport and antisense efficacy of nucleic acid analog into cells |
| WO2005013905A2 (en) * | 2003-08-07 | 2005-02-17 | Avi Biopharma, Inc. | SENSE ANTIVIRAL COMPOUND AND METHOD FOR TREATING ssRNA VIRAL INFECTION |
| US20050222068A1 (en) * | 2003-10-23 | 2005-10-06 | Mourich Dan V | Method and antisense composition for selective inhibition of HIV infection in hematopoietic cells |
| US20050171044A1 (en) * | 2003-12-24 | 2005-08-04 | Stein David A. | Oligonucleotide compound and method for treating nidovirus infections |
| WO2005072527A2 (en) | 2004-01-23 | 2005-08-11 | Avi Biopharma, Inc. | Antisense oligomers and methods for inducing immune tolerance and immunosuppression |
| US20050288246A1 (en) * | 2004-05-24 | 2005-12-29 | Iversen Patrick L | Peptide conjugated, inosine-substituted antisense oligomer compound and method |
| USRE48960E1 (en) | 2004-06-28 | 2022-03-08 | The University Of Western Australia | Antisense oligonucleotides for inducing exon skipping and methods of use thereof |
| ES2627917T3 (es) | 2004-06-28 | 2017-08-01 | The University Of Western Australia | Oligonucleótidos no codificantes para la inducción de la omisión exónica y métodos de uso de los mismos |
| AU2005327188C9 (en) * | 2004-07-02 | 2011-09-22 | Avi Biopharma, Inc. | Antisense antibacterial method and compound |
| US8129352B2 (en) | 2004-09-16 | 2012-03-06 | Avi Biopharma, Inc. | Antisense antiviral compound and method for treating ssRNA viral infection |
| US8357664B2 (en) * | 2004-10-26 | 2013-01-22 | Avi Biopharma, Inc. | Antisense antiviral compound and method for treating influenza viral infection |
| US7524829B2 (en) * | 2004-11-01 | 2009-04-28 | Avi Biopharma, Inc. | Antisense antiviral compounds and methods for treating a filovirus infection |
| JP2008526213A (ja) * | 2004-12-30 | 2008-07-24 | トッド エム． ハウザー， | 自己保護オリゴヌクレオチドを使用する、遺伝子発現を調節するための組成物および方法 |
| WO2006086667A2 (en) | 2005-02-09 | 2006-08-17 | Avi Bio Pharma, Inc. | Antisense composition and method for treating muscle atrophy |
| US20060240032A1 (en) * | 2005-03-31 | 2006-10-26 | Hinrichs David J | Immunomodulating compositions and methods for use in the treatment of human autoimmune diseases |
| US20060293268A1 (en) * | 2005-05-05 | 2006-12-28 | Rieder Aida E | Antisense antiviral compounds and methods for treating foot and mouth disease |
| US7790694B2 (en) * | 2005-07-13 | 2010-09-07 | Avi Biopharma Inc. | Antisense antibacterial method and compound |
| US8067571B2 (en) | 2005-07-13 | 2011-11-29 | Avi Biopharma, Inc. | Antibacterial antisense oligonucleotide and method |
| WO2007030691A2 (en) * | 2005-09-08 | 2007-03-15 | Avi Biopharma, Inc. | Antisense antiviral compound and method for treating picornavirus infection |
| AU2006287530A1 (en) * | 2005-09-08 | 2007-03-15 | Sarepta Therapeutics, Inc. | Antisense antiviral compound and method for treating picornavirus infection |
| US8501704B2 (en) * | 2005-11-08 | 2013-08-06 | Sarepta Therapeutics, Inc. | Immunosuppression compound and treatment method |
| CA2644262C (en) * | 2006-03-07 | 2016-01-05 | Avi Biopharma, Inc. | Antisense antiviral compound and method for treating arenavirus infection |
| US8785407B2 (en) * | 2006-05-10 | 2014-07-22 | Sarepta Therapeutics, Inc. | Antisense antiviral agent and method for treating ssRNA viral infection |
| LT2735568T (lt) * | 2006-05-10 | 2017-11-27 | Sarepta Therapeutics, Inc. | Oligonukleotido analogai, turintys katijonines jungtis tarp subvienetų |
| US20070265215A1 (en) * | 2006-05-11 | 2007-11-15 | Iversen Patrick L | Antisense restenosis composition and method |
| US20100016215A1 (en) * | 2007-06-29 | 2010-01-21 | Avi Biopharma, Inc. | Compound and method for treating myotonic dystrophy |
| CA2691673A1 (en) | 2007-06-29 | 2009-01-08 | Avi Biopharma, Inc. | Tissue specific peptide conjugates and methods |
| EP3133160B1 (en) | 2008-10-24 | 2018-12-12 | Sarepta Therapeutics, Inc. | Exon skipping compositions for dmd |
| US8592386B2 (en) * | 2008-12-17 | 2013-11-26 | Sarepta Therapeutics, Inc. | Antisense compositions and methods for modulating contact hypersensitivity or contact dermatitis |
| US20110269665A1 (en) | 2009-06-26 | 2011-11-03 | Avi Biopharma, Inc. | Compound and method for treating myotonic dystrophy |
| HUE040445T2 (hu) | 2009-11-12 | 2019-03-28 | Univ Western Australia | Antiszensz molekulák és eljárások betegségek kezelésére |
| AU2010319314C1 (en) | 2009-11-13 | 2016-09-01 | Sarepta Therapeutics, Inc. | Antisense antiviral compound and method for treating influenza viral infection |
| KR101981705B1 (ko) | 2010-05-28 | 2019-05-24 | 사렙타 쎄러퓨틱스, 인코퍼레이티드 | 변형된 서브유니트간 결합 및/또는 말단 그룹을 갖는 올리고뉴클레오타이드 유사체 |
| US8198429B2 (en) | 2010-08-09 | 2012-06-12 | Avi Biopharma, Inc. | Antisense antiviral compounds and methods for treating a filovirus infection |
| WO2012031243A2 (en) * | 2010-09-03 | 2012-03-08 | Avi Biopharma, Inc. | dsRNA MOLECULES COMPRISING OLIGONUCLEOTIDE ANALOGS HAVING MODIFIED INTERSUBUNIT LINKAGES AND/OR TERMINAL GROUPS |
| US9161948B2 (en) | 2011-05-05 | 2015-10-20 | Sarepta Therapeutics, Inc. | Peptide oligonucleotide conjugates |
| JP5850519B2 (ja) * | 2011-05-09 | 2016-02-03 | ネッパジーン株式会社 | モルフォリノ搭載バブルリポソームを有効成分としてなる筋ジストロフィー治療薬 |
| US20130085139A1 (en) | 2011-10-04 | 2013-04-04 | Royal Holloway And Bedford New College | Oligomers |
| KR20140097398A (ko) | 2011-11-18 | 2014-08-06 | 사렙타 쎄러퓨틱스, 인코퍼레이티드 | 기능적으로-변형된 올리고뉴클레오티드 및 이의 서브유니트 |
| US9217148B2 (en) | 2013-03-14 | 2015-12-22 | Sarepta Therapeutics, Inc. | Exon skipping compositions for treating muscular dystrophy |
| HK1220154A1 (zh) | 2013-03-15 | 2017-04-28 | Sarepta Therapeutics, Inc. | 改进的用於治疗肌营养不良的组合物 |
| MA41795A (fr) | 2015-03-18 | 2018-01-23 | Sarepta Therapeutics Inc | Exclusion d'un exon induite par des composés antisens dans la myostatine |
| US11020417B2 (en) | 2015-06-04 | 2021-06-01 | Sarepta Therapeutics, Inc | Methods and compounds for treatment of lymphocyte-related diseases and conditions |
| NZ755416A (en) | 2016-12-19 | 2023-05-26 | Sarepta Therapeutics Inc | Exon skipping oligomer conjugates for muscular dystrophy |
Family Cites Families (19)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| JP2528107B2 (ja) * | 1985-03-15 | 1996-08-28 | サマ−トン，ジエ−ムス | ポリヌクレオチド測定試薬と方法 |
| US5521063A (en) * | 1985-03-15 | 1996-05-28 | Antivirals Inc. | Polynucleotide reagent containing chiral subunits and methods of use |
| US5034506A (en) * | 1985-03-15 | 1991-07-23 | Anti-Gene Development Group | Uncharged morpholino-based polymers having achiral intersubunit linkages |
| US5506337A (en) * | 1985-03-15 | 1996-04-09 | Antivirals Inc. | Morpholino-subunit combinatorial library and method |
| US5235033A (en) * | 1985-03-15 | 1993-08-10 | Anti-Gene Development Group | Alpha-morpholino ribonucleoside derivatives and polymers thereof |
| US5378841A (en) * | 1989-12-20 | 1995-01-03 | Antivirals Inc. | Alpha-morpholino ribonucleoside derivatives and polymers thereof |
| ATE312834T1 (de) * | 1989-12-20 | 2005-12-15 | Avi Biopharma Inc | Ungeladene, auf morpholin basierende polymere mit chiralen, phosphor enthaltenden brücken zwischen den untereinheiten |
| US5843684A (en) | 1990-06-27 | 1998-12-01 | The Trustees Of Princeton University | Method for detecting pre-cancerous or cancerous cells using P90 antibodies or probes |
| US5756476A (en) * | 1992-01-14 | 1998-05-26 | The United States Of America As Represented By The Department Of Health And Human Services | Inhibition of cell proliferation using antisense oligonucleotides |
| BR9405707A (pt) * | 1993-01-07 | 1996-08-06 | Univ Jefferson | Inibiçao anti-sentido de c-myc para modular a proliferaçao de células de músculo liso |
| AU8019694A (en) * | 1993-10-15 | 1995-05-04 | Thomas Jefferson University | Inhibition of extracellular matrix synthesis by antisense compounds directed to nuclear proto-oncogenes |
| US6323184B1 (en) * | 1993-10-15 | 2001-11-27 | Thomas Jefferson University | Arteriovenous and venous graft treatments: methods and compositions |
| US5981731A (en) | 1994-05-31 | 1999-11-09 | Isis Pharmaceuticals, Inc. | Antisense oligonucleotide modulation of B-raf gene expression |
| US5563255A (en) * | 1994-05-31 | 1996-10-08 | Isis Pharmaceuticals, Inc. | Antisense oligonucleotide modulation of raf gene expression |
| US5656612A (en) * | 1994-05-31 | 1997-08-12 | Isis Pharmaceuticals, Inc. | Antisense oligonucleotide modulation of raf gene expression |
| CA2126952C (en) * | 1994-06-28 | 2010-12-14 | Sithian Pandian | Probe, kit, and method of amplification for increasing the sensitivity of nucleic acid hybridization assays |
| CA2139070C (en) * | 1994-12-23 | 2010-03-30 | Burton W. Blais | Method for enhancing detection ability of nucleic acid assays employing polymerase chain reaction |
| DE19502912A1 (de) * | 1995-01-31 | 1996-08-01 | Hoechst Ag | G-Cap Stabilisierte Oligonucleotide |
| US5877309A (en) * | 1997-08-13 | 1999-03-02 | Isis Pharmaceuticals, Inc. | Antisense oligonucleotides against JNK |
-
2000
- 2000-01-28 KR KR1020017009235A patent/KR20010102992A/ko not_active Withdrawn
- 2000-01-28 WO PCT/US2000/002475 patent/WO2000045167A2/en not_active Ceased
- 2000-01-28 CA CA002360997A patent/CA2360997A1/en not_active Abandoned
- 2000-01-28 US US09/493,494 patent/US6365351B1/en not_active Expired - Lifetime
- 2000-01-28 JP JP2000596368A patent/JP2002535015A/ja active Pending
- 2000-01-28 EP EP00911675A patent/EP1173561A2/en not_active Withdrawn
- 2000-01-28 AU AU33537/00A patent/AU778057B2/en not_active Ceased
- 2000-01-29 CA CA2359317A patent/CA2359317C/en not_active Expired - Lifetime
- 2000-01-29 AT AT00905838T patent/ATE445700T1/de not_active IP Right Cessation
- 2000-01-29 EP EP00905838A patent/EP1153129B1/en not_active Expired - Lifetime
- 2000-01-29 DE DE60043149T patent/DE60043149D1/de not_active Expired - Lifetime
- 2000-01-29 AU AU27459/00A patent/AU779128B2/en not_active Expired
- 2000-01-29 JP JP2000596139A patent/JP2002537230A/ja active Pending
- 2000-01-29 WO PCT/US2000/002331 patent/WO2000044897A1/en not_active Ceased
- 2000-01-29 KR KR1020017009506A patent/KR100684547B1/ko not_active Expired - Lifetime
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| JP3121599B2 (ja) | ｒａｆ遺伝子発現のアンチセンスオリゴヌクレオチド調節 | |
| US5656612A (en) | Antisense oligonucleotide modulation of raf gene expression | |
| KR101953074B1 (ko) | 올리고머 및 올리고머 접합체 | |
| KR102118429B1 (ko) | 마이크로rna 화합물 및 mir-21 활성 조절 방법 | |
| CA2174315C (en) | Oligonucleotide modulation of multidrug resistance-associated protein | |
| CN106434665B (zh) | 用于抑制乙型肝炎病毒的基因表达的组合物和方法 | |
| KR102214740B1 (ko) | Mir-122를 조정하기 위한 마이크로rna 화합물 및 방법 | |
| US20020068709A1 (en) | Therapeutic uses of LNA-modified oligonucleotides | |
| JP2011172597A (ja) | スプライス領域アンチセンス組成物および方法 | |
| JP2014507143A (ja) | アンチセンスオリゴヌクレオチド | |
| WO1996039415A1 (en) | ANTISENSE OLIGONUCLEOTIDE MODULATION OF raf GENE EXPRESSION | |
| CN114846140A (zh) | 用于治疗hbv的靶向hbv的治疗性寡核苷酸和tlr7激动剂的药物组合 | |
| EP0736093A1 (en) | ANTISENSE NUCLEIC ACIDS FOR THE PREVENTION AND TREATMENT OF DISORDERS IN WHICH EXPRESSION OF c-erbB PLAYS A ROLE | |
| WO2022248879A1 (en) | Composition and method for adar-mediated rna editing | |
| US6090626A (en) | Antisense oligonucleotide modulation of raf gene expression | |
| JP2004537030A5 (enExample) | ||
| EP0832214B1 (en) | Oligonucleotides specific for human papillomavirus | |
| US5952229A (en) | Antisense oligonucleotide modulation of raf gene expression | |
| WO2002048405A3 (en) | Non-invasive method for detecting target rna | |
| JP2002526072A (ja) | 遺伝子発現の調節のためのヘアピンハイブリダイザー分子 | |
| JP7813254B2 (ja) | Ｆｕｂｐ１発現を調節するための増強されたオリゴヌクレオチド | |
| Kiely | Recent advances in antisense technology | |
| WO1996035705A1 (en) | Inhibition of transcription factor-mediated transcriptional activation by oligomer strand invasion | |
| AU714142B2 (en) | Antisense oligonucleotide modulation of RAF gene expression | |
| HK40078455A (en) | Pharmaceutical combination of a therapeutic oligonucleotide targeting hbv and a tlr7 agonist for treatment of hbv |